ARTICLE | Company News
NICE draft guidance recommends Daiichi's Lixiana
August 7, 2015 2:03 AM UTC
The U.K.'s NICE issued draft guidance recommending Lixiana edoxaban as an option to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation (AF) and one or more additional risk factors. Daiichi Sankyo Co. Ltd. (Tokyo:4568) markets the oral Factor Xa inhibitor.
The draft guidance recommends Lixiana as an alternative to warfarin. ...